Skip to main content
TipRanks
Go Ultimate75% OFF

Restart Life Sciences (HEAL) Stock Price & Analysis

10 Followers

HEAL Stock Chart & Stats

CA$0.07CA$0.00(0.00%)
At close: 4:00 PM EST
C$0.07C$0.08Sep 1Sep 16Oct 5Oct 20Nov 3Nov 13
Day’s Range
CAD 0.07 - CAD 0.07
52-Week Range
CAD 0.07 - CAD 0.14
Previous Close
CAD 0.07
Volume
N/A
Average Volume (3M)
53.13K
Market Cap
CAD 4.06M
Enterprise Value
CAD 4.75M
Total Cash (Recent Filing)
CAD 762.36K
Total Debt (Recent Filing)
CAD 348.35K
Price to Earnings (P/E)
―
Beta
0.09
Next Earnings
Dec 02, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Improved 2025 Equity Position

The return to positive equity improves the company’s financial foundation and reduces the immediate strain associated with an impaired capital base. Although historical volatility remains a concern, this stabilization may support financing access and provide greater flexibility for future operations.

Modest Leverage

Relatively low debt compared with equity limits fixed financial obligations and reduces the burden of interest or principal payments. This gives management more flexibility to allocate capital toward developing the business and provides some resilience if operating performance remains weak.

Improving Cash-burn Trend

The reduction in cash outflow from earlier trough years indicates some improvement in cash management or operating requirements. While the company is not yet self-sufficient, a less severe burn rate could extend available funding and provide more time to establish sustainable operations.

Bears Say

No Recurring Revenue Base

The absence of recurring revenue means the company has not demonstrated commercial traction or a dependable source of operating income. Without a proven revenue base, funding must support development before customer economics can be validated, increasing execution risk over the coming quarters.

Persistent Operating Losses

Recurring operating losses show that the current business model is not covering its ongoing cost base. The lack of improvement in core profitability limits internal reinvestment capacity and leaves future financial progress dependent on achieving meaningful revenue growth or reducing expenses.

Continued Reliance On External Capital

Negative operating and free cash flow indicate that the company cannot currently fund its activities from internally generated cash. Continued dependence on outside financing can dilute existing holders, constrain strategic choices, and increase vulnerability if capital becomes harder to secure.

HEAL FAQ

What was Restart Life Sciences’s price range in the past 12 months?
Restart Life Sciences lowest stock price was C$0.07 and its highest was C$0.14 in the past 12 months.
What is Restart Life Sciences’s market cap?
Restart Life Sciences’s market cap is C$4.06M.
When is Restart Life Sciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Restart Life Sciences’s earnings last quarter?
Restart Life Sciences released its earnings results on Aug 27, 2026. The company reported -C$0.017 earnings per share for the quarter.
Is Restart Life Sciences overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Restart Life Sciences pay dividends?
Restart Life Sciences does not currently pay dividends.
What is Restart Life Sciences’s EPS estimate?
Restart Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Restart Life Sciences have?
Restart Life Sciences has 62,506,542 shares outstanding.
What happened to Restart Life Sciences’s price movement after its last earnings report?
Restart Life Sciences reported an EPS of -C$0.017 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Restart Life Sciences?
Currently, no hedge funds are holding shares in TSE:HEAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology